Triptorelin vs Leuprolide — Peptide Comparison

At a Glance

Quickcomparison

Dose Range

Triptorelin

0.1 mg–22.5 mg mg

Leuprolide

3.75 mg–45 mg monthly or 3-month injections (depending on formulation)

Frequency

Once daily

Administration

Intramuscular injection

Subcutaneous injection (daily)

Cycle Length

Ongoing/indefinite

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefitratings

Hormone Regulation

Cancer Management

Endometriosis Relief

Endometriosis & Fibroid Relief

Hormone Control

Technical Data

Compoundspecifications

Molecular Formula

C64H82N18O13

Molecular Weight

1311.4 g/mol

Half-Life

2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)

Bioavailability

~100% (intramuscular/subcutaneous injection)

CAS Number

57773-63-4

C59H84N16O12

1209.4 g/mol

Approximately 2-6 hours (varies by route of administration)

~95% (subcutaneous injection)

74381-53-6

Protocols

Dosingtiers

starting

3.75 mg

Once every 4 weeks

Ongoing while indicated

FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].

standard

11.25 mg

Once every 12 weeks

FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].

advanced

22.5 mg

Once every 24 weeks

FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].

1 mg

Ongoing

The original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].

7.5 mg

Every month

The 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].

Every 3 months

The 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].

30-45 mg

Every 4-6 months

The longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].

Applications

Bestsuited for

Managing advanced prostate cancer when combined with other treatments

Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving severe endometriosis pain and symptoms

Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying puberty development in children with early sexual maturation

Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing advanced or metastatic prostate cancer

Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Controlling severe endometriosis pain

Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating symptomatic uterine fibroids

Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying early puberty in children

Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Hot flashes (very common in men)

Decreased libido and erectile dysfunction

Injection site pain or swelling

Nausea

Fatigue

Mood changes or depression

Joint or muscle pain

Headaches

Dizziness

Thinning hair

Decreased bone density (osteoporosis with long-term use)

QT prolongation (rare but serious cardiac effect)

Tumor flare (temporary worsening of cancer symptoms in first weeks)

Severe allergic reactions

Spinal cord compression risk in men with metastatic disease

Serious

Severe allergic reaction

Research Status

Safety& evidence

FDA Status

FDA approved for this use

Safety Overview

Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

xPregnancy (can affect fetal development)

xUndiagnosed vaginal bleeding

xKnown hypersensitivity to GnRH agonists

xSevere untreated depression

xActive spinal cord compression in prostate cancer (requires urgent decompression)

Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient.

xPregnancy or breastfeeding (teratogenic)

xActive bone metastases with spinal cord compression (increased fracture risk)

xAllergy to GnRH agonists or components

xSevere cardiovascular disease with QT prolongation risk

Decision Guide

Which isright for you?

Choose Triptorelin if...

Managing advanced prostate cancer when combined with other treatments

Relieving severe endometriosis pain and symptoms

Delaying puberty development in children with early sexual maturation

Choose Leuprolide if...

Managing advanced or metastatic prostate cancer

Controlling severe endometriosis pain

Treating symptomatic uterine fibroids

Delaying early puberty in children